Publications
iMTA has been at the frontier of health technology assessment in research for over 25 years. We collaborate with all health care stakeholders, while maintaining independence and always publishing results. Find our work below.
Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study [View]
Pitter, J.G., Csanádia, M., Szigetib, A., Lukácsb, G., Kovácsb, A., Moizsb, M., Repab, I., Zemplényia, A., Czypionka, T., Kraus, M., Rutten – van Molken, M.P.M.H. & Kaló, Z. (2019). Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study. Bmc Health Services Research 19(1): 131. Doi: 10.1186/s12913-019-3957-9
Determining the comparative value of pharmaceutical risk-sharing policies in non-small cell lung cancer using real-world data [View]
Holleman, M.S., Uyl-de Groot, C.A. de, Goodall, S. & Linden, N. van der (2019). Determining the comparative value of pharmaceutical risk-sharing policies in non-small cell lung cancer using real-world data. Value in Health 22(3): 322-331. Doi: 10.1016/j.jval.2018.08.007
Evaluation of Patient Registries Supporting Reimbursement Decisions: The Case of Oxaliplatin for Treatment of Stage III Colon Cancer [View]
Mohseninejad, L., Gils, C.W.M. van, Uyl-de Groot, C.A., Buskens, E. & Feenstra, T. (2015). Evaluation of Patient Registries Supporting Reimbursement Decisions: The Case of Oxaliplatin for Treatment of Stage III Colon Cancer. Value in Health 18(1): 84-90. Doi: 10.1016/j.jval.2014.10.008
Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? [View]
Franken, M.G., Gaultney, J.G., Blommestein, H.M., Huijgens, P.C., Sonneveld, P., Redekop, W.K. & Uyl – de Groot, C.A. (2014). Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Value in Health 17(2): 245-253. Doi: 10.1016/j.jval.2013.12.009
Access to expensive cancer drugs in Dutch daily practice: Should we be concerned? [View]
Blommestein, H.M., Franken, M.G., Verelst, S.G.R., Agthoven, M. van, Huijgens, P.C. & Uyl – de Groot, C.A. (2014). Access to expensive cancer drugs in Dutch daily practice: Should we be concerned? Netherlands Journal of Medicine 72(4): 235-241.
Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time [View]
Sandmann, F.G., Franken, M.G. & Steenhoek, A. (2013). Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. Health Policy 112(3): 285-296. Doi: 10.1016/j.healthpol.2013.03.006
Introduction of expensive pharmaceuticals in haematooncology in the Netherlands and throughout Europe
Groot MT, Huijgens PC, Uyl-de Groot CA (2006). Introduction of expensive pharmaceuticals in haematooncology in the Netherlands and throughout Europe. Eur J Hosp Pharm Pract 12: 30-36.